Truist Financial Raises Agios Pharmaceuticals (NASDAQ:AGIO) Price Target to $38.00

Agios Pharmaceuticals (NASDAQ:AGIO) had its price objective increased by equities research analysts at Truist Financial from $32.00 to $38.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Truist Financial’s price objective would suggest a potential upside of 30.81% from the stock’s previous close.

AGIO has been the subject of a number of other reports. Wall Street Zen lowered Agios Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, November 22nd. Leerink Partners upgraded shares of Agios Pharmaceuticals from a “market perform” rating to an “outperform” rating and lowered their price objective for the company from $40.00 to $34.00 in a research report on Thursday, November 20th. Royal Bank Of Canada downgraded shares of Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and dropped their target price for the stock from $57.00 to $28.00 in a research note on Wednesday, November 19th. Weiss Ratings reissued a “sell (d)” rating on shares of Agios Pharmaceuticals in a research note on Monday. Finally, The Goldman Sachs Group lowered their price target on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating for the company in a report on Thursday, November 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, four have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $36.67.

Agios Pharmaceuticals Trading Up 18.1%

AGIO stock traded up $4.46 during trading on Wednesday, hitting $29.05. 5,795,225 shares of the stock traded hands, compared to its average volume of 900,716. The stock has a market cap of $1.69 billion, a price-to-earnings ratio of -4.15 and a beta of 0.87. Agios Pharmaceuticals has a one year low of $22.24 and a one year high of $46.00. The company has a 50 day simple moving average of $34.53 and a 200 day simple moving average of $36.36.

Agios Pharmaceuticals (NASDAQ:AGIO) last posted its earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.78) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.93) by $0.15. The company had revenue of $12.88 million during the quarter, compared to analysts’ expectations of $10.49 million. Agios Pharmaceuticals had a negative net margin of 895.86% and a negative return on equity of 28.35%. Agios Pharmaceuticals’s quarterly revenue was up 43.3% compared to the same quarter last year. During the same quarter in the previous year, the company posted $16.22 earnings per share. As a group, analysts predict that Agios Pharmaceuticals will post -6.85 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, insider Sarah Gheuens sold 3,302 shares of the stock in a transaction that occurred on Monday, October 27th. The stock was sold at an average price of $43.92, for a total transaction of $145,023.84. Following the completion of the sale, the insider directly owned 61,727 shares of the company’s stock, valued at approximately $2,711,049.84. This represents a 5.08% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Cecilia Jones sold 3,651 shares of Agios Pharmaceuticals stock in a transaction that occurred on Friday, September 26th. The shares were sold at an average price of $36.77, for a total transaction of $134,247.27. Following the completion of the transaction, the chief financial officer directly owned 33,870 shares in the company, valued at approximately $1,245,399.90. The trade was a 9.73% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 7,553 shares of company stock worth $305,001 over the last quarter. 4.93% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in AGIO. First Horizon Corp acquired a new position in Agios Pharmaceuticals in the 3rd quarter worth $45,000. NewEdge Advisors LLC bought a new stake in shares of Agios Pharmaceuticals in the first quarter valued at about $40,000. Quantbot Technologies LP acquired a new position in shares of Agios Pharmaceuticals during the third quarter worth about $79,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of Agios Pharmaceuticals by 16.7% during the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,237 shares of the biopharmaceutical company’s stock worth $74,000 after buying an additional 320 shares in the last quarter. Finally, PNC Financial Services Group Inc. raised its position in Agios Pharmaceuticals by 23.4% in the 2nd quarter. PNC Financial Services Group Inc. now owns 4,419 shares of the biopharmaceutical company’s stock valued at $147,000 after buying an additional 837 shares during the last quarter.

Key Headlines Impacting Agios Pharmaceuticals

Here are the key news stories impacting Agios Pharmaceuticals this week:

• Positive Sentiment: FDA expanded approval: Mitapivat (AQVESME) is now approved for anemia in adults with alpha‑ or beta‑thalassemia, covering both non‑transfusion‑dependent and transfusion‑dependent patients — a meaningful label expansion that opens a new commercial market for Agios. GlobeNewswire: U.S. FDA Approves Agios’ AQVESME
• Positive Sentiment: Market reaction: News of the approval drove premarket and intraday upside as investors priced in new revenue potential and exclusivity for this indication. Reuters: Agios Pharma shares jump on FDA expansion
• Positive Sentiment: Analyst upgrade / price target: Bank of America raised its price target to $34 and maintained a “buy” rating, providing dealer support and signaling upside vs. the current price. Benzinga: BofA raises AGIO price target
• Neutral Sentiment: Commercial timing & investor outreach: Company says AQVESME expected to be available in late January 2026 and will host an investor call/webcast; PYRUKYND® remains Agios’ U.S. brand for PK deficiency (branding split may affect marketing plans). GlobeNewswire: Commercial timing & branding
• Neutral Sentiment: Trading halt: Trading was temporarily halted for AGIO with the stated reason “News pending” ahead of the announcement — a procedural action that often precedes significant corporate disclosures and can contribute to intraday volatility.
• Negative Sentiment: REMS requirement: The FDA approval label includes a Risk Evaluation and Mitigation Strategy (REMS), which may impose prescribing and monitoring obligations that could slow uptake or limit use in some settings. Zacks: Mitapivat FDA nod with REMS

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.